1672 Stock Overview
A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Ascletis Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.69 |
| 52 Week High | HK$1.97 |
| 52 Week Low | HK$0.76 |
| Beta | 0.57 |
| 11 Month Change | 22.46% |
| 3 Month Change | 113.92% |
| 1 Year Change | -11.98% |
| 33 Year Change | -44.59% |
| 5 Year Change | -48.79% |
| Change since IPO | -87.93% |
Recent News & Updates
Recent updates
Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans?
Oct 07
We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate
Dec 19We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely
Aug 23What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today
Nov 03Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth
Oct 13Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates
Aug 24Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation
May 19Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts
Mar 27We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely
Feb 08Shareholder Returns
| 1672 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 0.6% | -0.3% | -0.6% |
| 1Y | -12.0% | -15.2% | 9.6% |
Return vs Industry: 1672 exceeded the Hong Kong Biotechs industry which returned -15.2% over the past year.
Return vs Market: 1672 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 1672 volatility | |
|---|---|
| 1672 Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.2% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1672 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1672's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 219 | Jinzi Jason Wu | www.ascletis.com |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.
Ascletis Pharma Inc. Fundamentals Summary
| 1672 fundamental statistics | |
|---|---|
| Market cap | HK$1.73b |
| Earnings (TTM) | -HK$277.66m |
| Revenue (TTM) | HK$10.84m |
152.3x
P/S Ratio-5.9x
P/E RatioIs 1672 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1672 income statement (TTM) | |
|---|---|
| Revenue | CN¥10.09m |
| Cost of Revenue | CN¥22.72m |
| Gross Profit | -CN¥12.63m |
| Other Expenses | CN¥245.84m |
| Earnings | -CN¥258.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | -125.17% |
| Net Profit Margin | -2,561.68% |
| Debt/Equity Ratio | 0% |
How did 1672 perform over the long term?
See historical performance and comparison